panitumumab,abraxane,paclitaxel
takeda,amgen
['crc,(-ccrcc),(-tbcrc049),(-mccrcc),(-mbcrc)', 'dynamic', 'paradigm', 'gicsm', 'sequence,(-consequence)', 'gi ', '#gi']
gi update from #asco22: 1. paradigm trial crc- practice affirming, some questions remain
2. dynamic- not practice changing. study design not ideal.
3. sequence- really interesting. could be practice changing. looking for full paper. #gicsm 1/ 
Personal account. Med Onc. Associate Professor @queensoncology @QueensuPHS. #cancerpolicy #globaloncology #cancergroundshot. Pubs-https://t.co/DE00s50Vpj